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Abstract 
Statins, which are inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, are consi-
dered as one of the most important drugs and the drug of choice for reducing an abnormal choles-
terol level. Statins are normally used to decrease the risk of coronary heart disease (CHD), but 
they tend to be associated with liver adverse effects. The objective of this prospective study was to 
investigate the effect of atorvastatin therapy on the liver function in patients with CHD. Study 
comprised of 66 newly diagnosed CHD patients who were selected from UNRWA clinics in the Gaza 
Strip. The patients were clinically examined and treated with atorvastatin (10 - 40 mg/day). A 
questionnaire was used to collect the data concerning patient’s characteristics. Total cholesterol 
(TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), liver enzymes tests such as alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) and total and direct blood bilirubin were measured before starting 
treatment and after 3 and 6 months of treatment. The results showed a significant increase in the 
mean values of ALT, AST, total bilirubin and direct bilirubin levels after 3 months then decreased 
after the next 3 months, but they were higher than the baseline with insignificant association. 
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1. Introduction 
Coronary heart disease (CHD) is the principle cause of morbidity and mortality worldwide [1]. The main cause 
of CHD is atherosclerosis that develops in the arteries that encircle the heart and supply it with blood [2]. 
Many studies have proved the link between coronary heart disease and cholesterol. Framingham Study which 
is one of the first studies showed a direct link between high blood cholesterol levels and development of CHD. It 
showed a link between other risk factors, such as hypertension, cigarette smoking, male gender, family history, 
and age, with CHD development [3]. 
Dietary modification would reduce the levels of blood cholesterol by 10% - 20%, but for further reduction, 
cholesterol lowering drugs are usually required. The most recent drugs developed for this purpose are statins or 
3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors which used for prevention and treatment of CHD; 
they lower cholesterol levels by 20% - 30%, and even more at higher doses, and this has been clinically proven 
to produce an equivalent decrease in the risk of myocardial infarction and death [4]. Statins have become one of 
the best-selling medication classes to date since their introduction into the marketplace in 1986, and include the 
following drugs commercially available in the US: atorvastatin, lovastatin, pravastatin, fluvastatin, simvastatin 
and rosuvastatin [5]. Statins are highly effective in reducing cardiovascular mortality and are widely prescribed 
with best selling. More than 145 million prescriptions were written for statins in the US in 2005, including ator-
vastatin, the best selling prescription drug in the world [6] [7]. 
Statins considered the drugs of first choice for modifying lipid risk factors for CHD, in addition to reversible 
inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. They have an ability to produce large 
reductions in low-density lipoprotein cholesterol (LDL-C) and ability to increase HDL cholesterol (HDL-C) [8] 
[9]. Statins like all medications, have potential adverse effects. The most serious are liver and muscle adverse 
effects. Cognitive loss, neuropathy, sexual dysfunction and, pancreatic dysfunction are examples of other ad-
verse effects [7]. 
Hepatic dysfunction includes either liver enzymes elevations as a result of liver injury or liver function dis-
turbances. The last two were studied according to the current guidelines which recommend measuring trans-
aminases (ALT = alanine aminotransferase, AST = aspartate aminotransferase) levels before initiating therapy. 
12 weeks after starting therapy, signs of potential hepatotoxicity such as jaundice, malaise, fatigue, and lethargy 
should alert physicians to measure transaminase levels and liver function tests. Fractionated bilirubin levels are 
recommended to rule out hepatic injury [10]. 
Abnormal hepatic transaminase levels are recognized as an infrequent occurrence of statin therapy. In partic-
ular, the transaminases seem to increase within the first 3 and 6 months of therapy [11]. In the majority of clini-
cal trials, elevated ALT levels three times greater than the upper limit of normal on two or more measurements 
have been considered as a safety endpoint. It was found that 1% of patients receiving low to intermediate statins 
dose (10 - 40 mg daily ) and in 2% - 3% of patients on high dose therapy (80 mg/daily) ALT elevation occurs [12]. 
Because of the absence of data concerning the hepatic toxicity of statins in Palestine, the present study was 
performed to evaluate the  hepatic adverse effects of statins by measuring the serum ALT, AST activities and 
serum direct and total bilirubin concentration in a number of newly diagnosed patients with CHD. 
2. Subjects and Methods 
2.1. Study Design and Patient Population 
This study was undertaken over a period of 6 months from November 2010 till July 2011 in UNRWA health 
centers in Gaza Strip-Palestine. Ethical approval was obtained from the UNRWA and Helisinki committee in the 
Ministry of Health. 
2.2. Sample and Sampling 
Sixty six patients were newly diagnosed with CHD participated in the study, 37 males and 29 females, the mean 
age of both males and females was between 55 ± 10.3 years. The Patients were treated with atorvastatin at the-
rapeutic dose with a range of (10 - 40) mg daily once a day at bedtime according to cardiologist assessment. 
2.3. Inclusion Criteria 
1) Newly diagnosed patients with CHD. 
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2) Patients with normal liver functions and liver enzymes. 
3) Patients with abnormal liver functions and liver enzymes were excluded from the study. 
4) Patients with hepatitis B & C or any liver diseases or any disease which may cause alteration of liver func-
tion tests were excluded from the study. This may be aided by taking history, and physical and clinical examina-
tion of the patients 
5) Patients on continuous administration of statins treatment or other lipid lowering agents were also excluded 
from the study. 
6) Patients receiving other medications affecting liver functions or liver enzymes. 
2.4. Tools of the Study 
Patient’s data were collected from the medical record, an interview questionnaire and clinical examination. Co-
lorimetric methods were used for determination of total cholesterol [13], TG [14], HDL-C, LDL-C [15]. Photo-
metric colorimetric methods were used for determination of ALT, AST, and total and direct blood bilirubin. 
2.5. Statistical Design 
Data were analyzed using the statistical package for social science (SPSS) computer program version 16. De-
scriptive statistics were performed to describe all variables. Chi-square was used to investigate the association 
between the study variables. Paired T-test was used to study the differences between the variables means. The 
significant of the association was tested at an alpha level of P < 0.05. 
3. Study Results 
3.1. Patient Characteristics 
The patient characteristics, family history and lipid parameters are listed in Table 1. Fifty six percent of patients 
were with heart disease family history. Forty three percent of patients were smokers. Fifty seven percent were 
obese. All the participants were treated with atorvastatin (10 - 40 mg) with the majority (83%) were receiving a 
daily dose of 20 mg. 
 
Table 1. Patient characteristics and lipid parameters (n = 66). 
Patient characteristics All patients (n = 66) 
Male 56.1% 
Female 43.9% 
Age (years) [mean ± SD] 55 ± 10.3 
Family history of heart disease (%) 56.1 
Current smokers (%) 43.9 
Systolic BP (mmHg) [mean ± SD] 131.8 ± 13.5 
Diastolic BP (mmHg) [mean ± SD] 80.3.0 ± 8.2 
BMI ₰ (kg/m2) [mean ± SD] 30.9 ± 5.8 
BMI > 30 kg/m2 (%) 57.6 
Lipid parameters  
High total cholesterol (mg/dL) (%) 15.1 
High LDL-C (mg/dL) (%) 13.6 
High HDL-C (mg/dL) (%) 13.6 
High triglycerides (mg/dL) (%) 15 
Atorvastatin dose  
10 mg (%) 14 
20 mg (%) 83 
40 mg (%) 3 
Drug Interaction  
Diltiazem  
₰BMI = body mass Index 
*The classification according to NCEP [16], all the values are mg/dL. 
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3.2. The Effect of Statins on Liver Function 
3.2.1. Distribution of Study Population by the Liver Transaminases and Bilirubin 
According to the data shown in Table 2, 98.5% of the study population was within the normal ALT range. This 
percent decreased after 3 months to 81.8% and accordingly, 18.2% of the patients have abnormal values of ALT. 
On the other hand, all the patients had normal values of AST at the baseline. However, the percent of patients 
with abnormal high AST levels increased to 9.1% at the first three months of the study and then decreased to 3% 
after 6 months. Similarly, the percent of abnormal total and direct bilirubin increased in the first three months 
and then decreased at the last three months of the study period. 
3.2.2. The Effect of Statins on Liver Function and Liver Enzymes 
1) The effect of statins on liver transaminases 
Results shown in Table 3 indicated a significant increase in the mean values of ALT and AST levels after 3 
months of statins treatment compared to pre-treatment values. The new attainable levels of ALT and AST after 6 
months of treatment were higher than the baseline levels; however, they were statistically insignificant. 
2) The effect of statins on bilirubin 
The data shown in Table 4 pointed out a significant increase in the mean values of total and direct bilirubin 
after 3 months of statins treatment compared to pretreatment values. The new attainable levels of bilirubin after 
6 months were higher than the baseline levels, however, they were statistically insignificant (p > 0.05). 
4. Disscussion 
4.1. The Relationship between Statins and Aminotransferases 
The results of the current study revealed a mild to moderate asymptomatic but statistically significant elevations 
 
Table 2. Distribution of study population by the liver transaminases and bilirubin variables (n = 66). 
Variable 
Baseline After 3 Months After 6 Months 
Number (%) Number (%) Number (%) 
ALT 
Normal 65 98.5 54 81.8 61 92.4 
Abnormal 1 1.5 12 18.2 5 7.6 
AST 
Normal 66 100 60 90.9 64 97.0 
Abnormal - - 6 9.1 2 3 
Total bilirubin 
Normal 66 100 61 92.4 64 97.0 
Abnormal - - 5 7.6 2 3.0 
Direct bilirubin 
Normal 64 97.0 63 95.5 64 97.0 
Abnormal 2 3 3 4.5 2 3 
 
Table 3. Levels of liver enzymes ALT, AST (U/L) before and at 3 and 6 months during the study period (n = 66). 
Variable Time Number Mean SD t-test p-value 
ALT 
Before Atorvastatin 66 18.95 7.28 −4.3 0.00a 
After 3 months of Atorvastatin 66 26.95 14.43 −1.7 0.09b 
After 6 months of Atorvastatin 66 21.36 10.28 2.8 0.006c 
AST 
Before Statins 66 18.61 6.305 −3.113 0.00a 
After 3 months of Statins 66 24.85 12.329 −4.884 0.171b 
After 6 months of Statins 66 20.61 9.915 0.978 0.012c 
aDifference of means between before Atorvastatin and 3 months after Atorvastatin; bDifference of means between before Atorvastatin and 6 months 
after Atorvastatin; cDifference of means between 3 months after Atorvastatin and 6 months after Atorvastatin. 
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Table 4. Levels of total and direct bilirubin for the patients before and at 3 and 6 months during study period (n = 66). 
Variable Time Number Mean SD t-test p-value 
Total Bilirubin 
Before Atorvastatin 66 0.659 0.218 −4.948 0.00a 
After 3 months of Atorvastatin 66 0.796 0.246 −1.054 0.296b 
After 6 months of Atorvastatin 66 0.699 0.211 2.543 0.013c 
Direct Bilirubin 
Before Atorvastatin 66 0.227 0.137 −2.115 0.038a 
After 3 months of Atorvastatin 66 0.297 0.249 −1.767 0.082b 
After 6 months of Atorvastatin 66 0.265 0.135 1.237 0.221c 
aDifference of means between before statins and 3 months after atorvastatin; bDifference of means between before statins and 6 months after atorvas-
tatin; cDifference of means between 3 months after statins and 6 months after atorvastatin. 
 
of aminotransferases exceeding 1X upper normal limits (UNL). However, no case was with severe elevation 
higher than 3X UNL was found. This elevation can be identified as “transaminitis” in which liver enzyme levels 
are elevated in the absence of proven hepatotoxicity [17]. Furthermore, the obtained results showed a significant 
increase in the mean values of ALT levels after 3 and 6 months of statins treatment compared to pre-treatment 
values. On the other hand, the mean values of AST increased significantly only at the first 3 months post-statins 
treatment compared to the pre-treatment values (p < 0.001) and then decreased back to an insignificant level 
(20.61 ± 9.915 U/L) at the last three months. This difference between the ALT and AST elevation, post-statin 
treatment, may be related to the higher sensitivity of ALT to hepatic inflammation [18]. 
The results obtained were similar to the results found in a study provided by Chang & Schiano [19] who de-
clared that generally mild aminotransferases elevation associated with statin occurs within the first 12 weeks and 
is asymptomatic and improves spontaneously. The incidence ranges from 0% to 3%. Similarly, another study 
conducted by Al-Jubori & Mahmood [20] demonstrated a mild elevation of ALT and AST activities less than 3 
X the UNL post-statin treatments. On the other hand, several studies reported higher elevation values of ALT 
and AST activities more than 3X UNL [21]-[23]. Furthermore, several clinical cases of autoimmune hepatitis an 
acute cholestatic hepatitis were reported after atorvastatin treatment [24]. 
Castro [25] reported another case of 72 years-old man who developed acute cholestatic hepatitis after ator-
vastatin treatment at a higher dose than lower doses. After treatment discontinuation, the patient made a full re-
covery. Elevations of all measured hepatic parameters in the current study were observed. This may indicate that 
the pattern of hepatotoxicity caused by atorvastatin is a mixed pattern of liver damage and hepatocellular dam-
age [6]. 
Review of literature revealed varied periods of therapy at which the hepatic effect of statins was detected; 3 
and 6 months [11]; 4 months [26]; 2 - 4 times during the first year of treatment and 1 - 2 times per year subse-
quently [27]. 
The mechanisms behind these adverse effects are unclear, but a few possibilities have been suggested. It has 
been noted that statins can induce a transient acute phase response on initiation, especially at high doses [28] 
[29] and this may represent a transient chemical hepatitis due to disturbance of the cholesterol-bile acid path-
ways [30]. Moreover, it was speculated that the increased transaminases serum activity reflects alterations to the 
hepatocellular membrane (e.g., enhanced permeability) that permit leakage of these intracellular proteins [21]. 
The former mechanisms appear to be a pharmacodynamic effects rather than a representation of cellular and 
particularly liver toxicity [31]. 
4.2. The Relationship between Statins and Bilirubin 
The published data on the effect of statins on bilirubin are rare in comparison with articles related to the effect of 
statins on liver transaminases. Some studies assessed total bilirubin [17]. As one of the liver parameters; some 
assessed fractioned bilirubin [12] and others assessed both [32]. Since 2001, a total bilirubin level of more than 
2X UNL has been used in combination to transaminases to define clinically-significant abnormal liver function, 
with confirmation required by additional clinical and laboratory data [33]. One case of a 68 years old man was 
on atorvastatin 20 mg/day, showed abnormal elevation in both total and direct bilirubin which was 7.4 and 4.5 
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mg/dl respectively in addition to transaminitis [32]. 
In this study both total and direct bilirubin were measured and the relationship between them and statins 
treatment were analyzed. According to the results obtained, there was a significant increase in the mean values 
of total bilirubin in the first 3 months of study period increased from (0.659 ± 0.2179 mg/dL) to (0.796 ± 0.2461 
mg/dL), at (p < 0.01). This is similar to the results obtained in a previous study in which patients on simavastatin 
and lovastatin (10 - 20 mg) showed statistically significant elevation in the total bilirubin level [20]. On the other 
hand, there was a mild increase, however, statistically insignificant, in the direct bilirubin mean value after 3 and 
6 months of atorvastatin treatment. This insignificant relation may be due to the antioxidant effect of statins 
which is one of the most important of statins pleiotropic properties; a recent study on mice administered statins 
showed that statins increase the plasma antioxidant level [34]. 
Statins have also been reported to up-regulate antioxidant enzymes: catalase, superoxide dismutase and gluta-
thione peroxidase, which eliminate free radicals by the generation of water and oxygen [35]-[37]. Thus that 
might be related to the short term of period of the study and the small sample size. 
4.3. Some Risk Factors for Statins Liver Adverse Effects 
The incidence of statins-induced hepatotoxicity is uncommon events and the reported incidence is very low [38]. 
The incidence of statin-induced liver injury may increase because of the presence other risk factors which could 
increase patient liver-injury susceptibility. Three risk factors (obesity, dose, drug interaction) were studied. 
Several studies showed that obese individuals may have higher levels of serum transaminases than their lean 
counterparts [39]. However; other studies concluded that the administration of statins to obese patients seems to 
be equally safe with the use of these drugs in lean subjects [40]. 
The results of the current study show that there was no significant relationship between liver enzyme eleva-
tion and the dose of statins. This was in agreement of Shepherd [41]. And it was different from other studies that 
indicate that the enzymes and bilirubin emerge with higher doses. The results of this study may be not real due 
to that no high dose (80 mg) was administered from any of the patients, such (10, 20, 40 mg) doses which were 
available in the study were classified as low and moderate doses respectively [42] [43]. 
Shepherd [44] found that the rate of liver enzyme elevation with atorvastatin 80 mg/dL was four times greater 
compared with atorvastatin 10 mg/dL. Thus, hepatotoxic effects were related to the drug and dose used. Bhard-
waj & Chalasani [6] also found that higher doses leading to greater frequency of transminases elevations and 
described it a dose-related phenomenon. The results of this study might be different to the new studies due to the 
range of doses used (10 - 40 mg) is considered a low to moderate dose, no patient was on higher doses (80 mg). 
In our study, the selected patients were asked about the most common drugs that interact with atorvastatin. 
The results showed that there was no drug interaction between these drugs and atorvastatin except diltiazem. 
There was a significant relationship between diltiazem co-administered with statins and transminitis. This result 
was similar to Law & Rudnicka [45] who reported that diltiazem increases the plasma levels of statins, and may 
lead to statin-related adverse effects. Gladding [46] found that the toxicity of statins metabolized by cytochrome 
P450 3A4, such as simvastatin and atorvastatin, is enhanced when the drugs are prescribed in high doses with 
diltiazem. 
5. Conclusion 
In conclusion, the effects of atorvastatin on both blood tranaminases and bilirubin levels support the previous 
findings of potential statin hepatotoxicity. Therefore, the FDA labeling information for all statins recommends 
liver function testing before putting a patient on a statins, 12 weeks after initiation, at any dose increase, and 
“periodically” for long-term maintenance therapy. These recommendations are based on expert opinion only, 
because most data suggest that significant liver damage from statins is very rare and that routine monitoring of 
liver enzymes is not necessary. The ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins 
agrees with the FDA, although it specifies “periodically” to mean annually [47]. 
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